Dr. Alan H. Bryce, MD, discusses the newest advances and research in prostate cancer treatments that target androgen receptors, such as BET inhibitors and CYP17 inhibitors, as opposed to chemotherapeutic and radiopharmaceutical approaches.
Read More
Erik P. Castle, MD, explains approaches to improving ERAS for non-muscle invasive bladder cancer patients who have gone through radical cystectomy and other surgeries. He emphasized the benefits of administering Alvimopan in this process.
Read More
Dr. Michael S. Cookson, MD, MMHC, discusses the advantages of using MRI for the enhanced detection of prostate cancer, as opposed to traditional biopsy.
Read More
David C. Beyer, MD, reviews recent data regarding external beam radiation, brachytherapy, and androgen deprivation therapy (ADT) as it relates to radiation oncology and prostate cancer treatment.
Read More
Dr. Phillip J. Koo, MD, discusses the use of radiopharmaceuticals in prostate cancer treatment, as well as the area of theranostics. He goes into detail on the process of choosing these radiopharmaceuticals and trying to determine the best ones to use in various situations in regards to prostate cancer.
Read More